27 Ces Urol 2023; 27(1): 17–28 PŘEHLEDOVÉ ČLÁNKY 33. Padma‑Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology. 2006; 68(2): 386–391. 34. Sokolakis I, Hatzichristodoulou G. Clinical studies on low intensity extracorporeal shockwave therapy for erectile dysfunction: a systematic review and meta‑analysis of randomised controlled trials. Int J Impot Res. 2019; 31(3): 177–194. 35. Capogrosso P, Frey A, Jensen CFS, et al. Low‑Intensity Shock Wave Therapy in Sexual Medicine‑Clinical Recommendations from the European Society of Sexual Medicine (ESSM). J Sex Med. 2019; 16(10): 1490–1505. 36. Kitrey ND, Gruenwald I, Appel B, et al. Penile Low Intensity Shock Wave Treatment is Able to Shift PDE5i Nonresponders to Responders: A Double‑Blind, Sham Controlled Study. J Urol. 2016; 195(5): 1550–1555. 37. Bechara A, Casabé A, De Bonis W, Ciciclia PG. Twelve‑Month Efficacy and Safety of Low‑Intensity Shockwave Therapy for Erectile Dysfunction in Patients Who Do Not Respond to Phosphodiesterase Type 5 Inhibitors. Sex Med. 2016; 4(4): e225-e232. 38. Vinay J, Moreno D, Rajmil O, Ruiz‑Castañe E, Sanchez‑Curbelo J. Penile low intensity shock wave treatment for PDE5I refractory erectile dysfunction: a randomized double‑blind sham‑controlled clinical trial. World J Urol. 2021; 39(6): 2217–2222. 39. Kalyvianakis D, Mykoniatis I, Memmos E, et al. Low‑intensity shockwave therapy (LiST) for erectile dysfunction: a randomized clinical trial assessing the impact of energy flux density (EFD) and frequency of sessions. Int J Impot Res. 2020; 32(3): 329–337. 40. Chung E, Cartmill R. Evaluation of Long‑Term Clinical Outcomes and Patient Satisfaction Rate Following Low Intensity Shock Wave Therapy in Men With Erectile Dysfunction: A Minimum 5-Year Follow‑Up on a Prospective Open‑Label Single‑Arm Clinical Study. Sex Med. 2021; 9(4): 100384. 41. Levine LA, Dimitriou RJ. Vacuum constriction and external erection devices in erectile dysfunction. Urol Clin North Am. 2001; 28(2): 335–41. 42. Yuan J, Hoang AN, Romero CA, et al. Vacuum therapy in erectile dysfunction – science and clinical evidence. Int J Impot Res. 2010; 22(4): 211–219. 43. Cookson MS, Nadig PW. Long‑term results with vacuum constriction device. J Urol. 1993; 149(2): 290–294. 44. Lewis RW, Witherington R. External vacuum therapy for erectile dysfunction: use and results. World J Urol. 1997; 15(1): 78–82. 45. Trost LW, Munarriz R, Wang R, Morey A, Levine L. External Mechanical Devices and Vascular Surgery for Erectile Dysfunction. J Sex Med. 2016; 13(11): 1579–1617. 46. Shabsigh R, Padma‑Nathan H, Gittleman M, et al. Intracavernous alprostadil alfadex is more effi‑ cacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. Urology. 2000; 55(1): 109-113. 47. Coombs PG, Heck M, Guhring P, Narus J, Mulhall JP. A review of outcomes of an intracavernosal injection therapy programme. BJU Int. 2012; 110(11): 1787–1791. 48. Porst H, Burnett A, Brock G, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013; 10(1): 130–171. 49. Eardley I, Donatucci C, Corbin J, et al. Pharmacotherapy for erectile dysfunction. J Sex Med. 2010; 7(1 Pt 2): 524–540. 50. Lakin MM, Montague DK, VanderBrug Medendorp S, Tesar L, Schover LR. Intracavernous injection therapy: analysis of results and complications. J Urol. 1990; 143(6): 1138–1141. 51. Gupta R, Kirschen J, Barrow RC 2nd, Eid JF. Predictors of success and risk factors for attrition in the use of intracavernous injection. J Urol. 1997; 157(5): 1681–1686.
RkJQdWJsaXNoZXIy NDA4Mjc=